SynthesisInternational journal of molecular sciences2025
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond wound closure: translational opportunities and barriers of mesenchymal stem cells and their extracellular vesicles in burn management.Frontiers in cell and developmental biology · 2026Review
- Research trends and hotspots in Adipose-Derived Stem Cell applications for peripheral nerve regeneration from 2000 to 2025: a bibliometrics visualization study.Brain & spine · 2026Review
- Biomaterial-Based Nucleic Acid Delivery Systems for In Situ Tissue Engineering and Regenerative Medicine.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Allogeneic adipose stem cells (AASCs) are increasingly recognized for their potential in regenerative medicine. They offer a promising alternative to autologous cells, with potential advantages such as availability and reduced morbidity in the recipient. Therefore, the aim of the present systematic review was to explore AASCs applications in various diseases and conditions, including skin lesions, Crohn's disease, glandular dysfunction, kidney disease, spinal muscular atrophy and osteoarthritis. This review was conducted according to PRISMA guidelines; PubMed, Embase and Web of Science databases were used to search for studies published between 2011 and 2024, without language restrictions. Our review was strictly limited to the inclusion of controlled clinical trials to ensure the relevance and quality of the data. After screening, 22 articles were retained, with a total of 953 patients that met the established inclusion criteria. The data obtained from these studies showed that AASCs have promising efficacy in improving scars and ulcers, managing Crohn's disease, and treating glandular dysfunction and kidney disease. In spinal muscular atrophy and osteoarthritis, preliminary results also suggested potential benefits. AASCs-based treatments were well tolerated with no major adverse effects, thus emphasizing their favorable safety profile. AASCs show a significant potential for a variety of clinical applications, but the results must be interpreted with caution due to the methodological limitations of the included studies. Well-designed Phase III clinical trials are needed to confirm these promising results and ensure the safe and effective use of AASCs in clinical practice. This review highlights the importance of the standardization of procedures and raises relevant ethical issues related to the use of donor cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.